In these challenging times to address the #pandemic, the entire #FrenchHealthcare ecosystem is committed to bringing #SolutionsForCOVID19. Because mass testing is now a PRIORITY. Every day, #French companies are actively working on the development of #moleculardiagnostics #TESTS to effectively trace and contain the #virus. #Innovative #Research is also in place to develop #serological #tests to identify the presence of antibodies against #Covid19. TODAY, #FrenchHealthcare is offering a wide range of #SOLUTIONS to fight COVID-19. #FrenchHealthcare #ChooseFrance Special thanks to: CERBA HEALTHCARE ILSA Innobiochips Mobidiag xRapid Group NG BIOTECH #Athotis Medicen Paris Region BioValley France Eurobiomed Atlanpole Lyonbiopôle Eurasante - Health Cluster Clubster NSL French Healthcare Association SNITEM Leem Business France Business France – Santé Ministère des Affaires étrangères français Jean-Patrick LAJONCHERE Christophe Lecourtier Frédéric ROSSI Pascal Cagni France Biotech
French Healthcare’s Post
More Relevant Posts
-
[#medtech #handisport #attractiveness] Discover how France supports Handisport France will host the Summer Paralympic Games, with 22 sports on the program from August 28 to September 8, 2024. Ministère des Sports et des Jeux Olympiques et Paralympiques Paris 2024 - Comité d'organisation des Jeux Olympiques et Paralympiques de 2024 Ministère de l'Europe et des Affaires étrangères Business France (Invest in France) #FrenchHealthcare #ChooseFrance
To view or add a comment, sign in
-
[#research #oncology] The new entity officially launched its activities on January 17, 2024. Three main areas of research have been identified. olivier delattre #FrenchHealthcare #ChooseFrance
To view or add a comment, sign in
-
Immunothérapie : une approche prometteuse basée sur une découverte de l’Institut Curie va être développée par Biomunex Partenaires depuis 2019, l’Institut Curie et BIOMUNEX PHARMACEUTICALS annoncent une nouvelle étape dans leur collaboration de recherche stratégique. Biomunex signe un accord de licence exclusif avec l’Institut Curie pour le développement clinique d’une nouvelle catégorie d’anticorps, capables de cibler, d’engager et de rediriger spécifiquement les cellules MAIT pour détruire les cellules cancéreuses. 👉 Un pas de plus vers de nouvelles immunothérapies de pointe, plus sûres et plus efficaces, au bénéfice des patients. Pour en savoir plus :
Immunothérapie : une approche prometteuse basée sur une découverte de l’Institut Curie va être développée par Biomunex
techtransfer.institut-curie.org
To view or add a comment, sign in
-
[#biotech #pharma #attractiveness] The world leader in the development and production of microbiota-based therapeutic solutions will double its production capacity to move from clinical to industrial scale. Biose Industrie #FrenchHealthcare #ChooseFrance
Biose Industrie invests 80 million euros to expand its Aurillac site - Actualités | French Healthcare
frenchhealthcare.fr
To view or add a comment, sign in
-
[#research #digitalhealth #oncology] The Institut de Cancérologie de l'Ouest (ICO) is the winner of the France 2030 Call for Projects, alongside the Institut Bergonié and the Centre Hospitalier Intercommunal Mont de Marsan - Pays des Sources and the Digital Medical Hub. #FrenchHealthcare #ChooseFrance
A new digital health experimentation center entirely dedicated to oncology - Actualités | French Healthcare
frenchhealthcare.fr
To view or add a comment, sign in
-
[#biotech #research] The biotech has just obtained authorization to start a clinical trial in France for its gene therapy targeting deficiency of the gene coding for otoferlin. Sensorion #FrenchHealthcare #ChooseFrance
Sensorion begins clinical trials to treat deaf babies - Actualités | French Healthcare
frenchhealthcare.fr
To view or add a comment, sign in
-
[#medtech] For the upcoming Paralympic Games, PROTEOR is a French medtech company that equips top athletes #FrenchHealthcare #ChooseFrance
Les retombées presse de PROTEOR 📝 A Seurre, PROTEOR équipe les athlètes pour les Jeux paralympiques. "Tennis de table, équitation, athlétisme… Pour Proteor, un handicap ne doit pas freiner la pratique sportive." "Dans la pratique, pour une même discipline sportive, selon le handicap, la solution développée sera différente. Ainsi, parmi la vingtaine de sportifs de haut-niveau équipés par l’entreprise, il y a plusieurs cavaliers. Quand l’un profite d’une selle spécifique, un autre monte avec des prothèses." Retrouvez l'intégralité de l'article sur 👉 https://lnkd.in/ereGmqbQ 📝 La Gazette Bourgogne #proteor #weareproteor #humanfirt #magazine #lagazette #pratique #sportive #athlete
A Seurre, Proteor équipe les athlètes pour les Jeux paralympiques | La Gazette Bourgogne
gazettebourgogne.fr
To view or add a comment, sign in
-
[#research #oncology] At the end of 2023, the Hematology-Transplant Department at Hôpital Saint-Louis AP-HP celebrated its 50th anniversary, providing an opportunity to look back on the major scientific advances that have marked these five decades. #FrenchHealthcare #ChooseFrance
Hôpital Saint-Louis AP-HP: 50 years at the forefront of allogeneicbone marrow transplantation - Actualités | French Healthcare
frenchhealthcare.fr
To view or add a comment, sign in
-
Back to Arab Health Exhibition 🙏A big thank you to all visitors to the French Pavilions! The 87 French companies, united under the French Healthcare banner, express their gratitude for this memorable event! Guess who will be back in 2025! In the meantime, visit our page and download our catalog. https://lnkd.in/dFYY3sgN Many thanks also to our partners Région Centre-Val de Loire Eurasanté CCI GRAND EST 🇫🇷 French Healthcare Association SNITEM for this wonderful edition!
To view or add a comment, sign in
-
🎉 60 million euros series A 🎉 I am beyond excited to share that AQEMIA raised another €30M, which grows our series A to a total of €60M, to accelerate even more on our proprietary pipeline of therapeutic molecules. 🎯 Fundraising Goals: - Getting closer to the clinic — To push our proprietary, internal, drug discovery programs closer to the clinic! 3 internal projects are already being tested in the animal. The tech works amazing - we move forward. Fast. - De-multiplying internal projects — To de-multiply the number of internal projects. We will find many new drugs, not one. That's our vision since day 1. - Recruiting a Global Team incl. Execs — To bolster our dream team. 🤝 Our investors: - The new round is led by Wendel. Welcome on board, Victoire Laurenty! We are perfectly aligned with a long term, strategic goal of building a next gen, global #pharma and #biotech leader. - All historical investors also participated, especially Laurent Higueret from Bpifrance Large Venture, Antoine Zins from Eurazeo Investment Manager and David Sourdive from Elaia. 🔬 What This Means: - This fundraising to fuel our internal pipeline of drug discovery programs is a strategic milestone in our journey, 4 years only after Emmanuelle Martiano Rolland and I spin-out from Ecole normale supérieure-PSL Research University and Centre national de la recherche scientifique. - We continue to prove again and again the real-world value we bring to drug discovery with our unique technology mixing genAI and rigorous, deep physics. A concrete example? Our recently announced $140M partnership with one of top pharma company. - We are eager to put our first molecules in the clinic. - We are proud to define new ways of making drug discoveries, for the benefits of patients waiting for solutions. We believe in the immense potential of blending unique physics with GenAI and devising the right operational model to unlock its full power. 🙏 Acknowledgments: - A heartfelt thank you to our incredible Aqemia team, especially Nicolas Canouï and Marion Birolini, and to our investors. Thank you Sofia DAHOUNE for the past 4 years together. Welcome on board, David Sourdive! - Grateful for the unwavering support of our community, and ecosystem. 🚀 The Future: - As AQEMIA takes this monumental stride, we invite you to join us in this transformative journey. - Let's redefine the future of drug discovery together! 👉 Stay tuned for all the details in our press release below! #drugdiscovery #drugdesign #genAI #Quantumphysics #deeptech #biotech cc: Jean-Noël Barrot, Maïlys Ferrere, Paul-François Fournier, Nicolas Dufourcq, Sylvie Retailleau, Bruno Le Maire, Bruno Rostand, Antoine Petit, Ingrid Delval, Alain Fuchs, Clara Chappaz, Lise ALTER, Franck Mouthon cc: Antoine Izsak, Diane Schiller, Laurent Mignon, Jérôme Michiels, David Darmon, Caroline Decaux, Déborah Loye, Louisa Mesnard, Marine Choplain, Louisa Mesnard
AQEMIA Boosts Series A Funding to €60M to Accelerate on its Proprietary Therapeutic Pipeline
businesswire.com
To view or add a comment, sign in
9,628 followers